SCORE

33

SLNO: Soleno Therapeutics is a Sell


The current rating for SLNO is 33, which is 52% below its historic median rating of 50. This indicates higher risk than normal.


The rating is currently showing a lower than normal reading, suggesting risk levels could be higher than normal and additional caution is advised.